Treatment of primary aldosteronism

被引:23
作者
Quinkler, Marcus [2 ]
Stewart, Paul M. [1 ]
机构
[1] Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Inst Biomed Res, Birmingham B15 2TH, W Midlands, England
[2] Charite, D-10117 Berlin, Germany
关键词
primary aldosteronism; mineralocorticoid receptor; adrenalectomy; spironolactone; eplerenone; conn's adenoma; GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; CONVERTING ENZYME-INHIBITOR; CALCIUM-CHANNEL BLOCKADE; INTIMA-MEDIA THICKNESS; PLASMA-RENIN ACTIVITY; ESSENTIAL-HYPERTENSION; PRIMARY HYPERALDOSTERONISM; RESISTANT HYPERTENSION; HYPER-ALDOSTERONISM; BLOOD-PRESSURE;
D O I
10.1016/j.beem.2010.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of primary hyperaldosteronism approaches 10% of all hypertensive patients, and besides efficient diagnostic procedures, effective treatment is of increasing importance to reverse increased morbidity and mortality. Aldosterone-producing adenoma and unilateral adrenal hyperplasia are amenable to cure by endoscopic adrenalectomy. Bilateral adrenal hyperplasia (micro- or macronodular), which comprises two-thirds of primary hyperaldosteronism, is treated primarily by mineralocorticoid receptor antagonists (starting dose 12.5-25 mg/day spironolactone with titration up to 100 mg/day, alternatively 50-100 mg/day eplerenone). If blood pressure is not normalised by this first-line treatment, additional treatment with potassium-sparing diuretics (amiloride or triamterene) or calcium channel antagonists is necessary. The start of medication should be closely monitored by serum electrolyte and creatinine controls. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:923 / 932
页数:10
相关论文
共 97 条
[1]   Clinical review: Adrenocortical carcinoma: Clinical update [J].
Allolio, Bruno ;
Fassnacht, Martin .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06) :2027-2037
[2]  
Amar L, 2010, HYPERTENSION 0913
[3]  
BAER L, 1970, CIRC RES, V27, pI203
[4]   Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism [J].
Bernini, Giampaolo ;
Galetta, Fabio ;
Franzoni, Ferdinando ;
Bardini, Michele ;
Taurino, Chiara ;
Bernardini, Melania ;
Ghiadoni, Lorenzo ;
Bernini, Matteo ;
Santoro, Gino ;
Salvetti, Antonio .
JOURNAL OF HYPERTENSION, 2008, 26 (12) :2399-2405
[5]   DIAGNOSIS AND TREATMENT OF PRIMARY HYPERALDOSTERONISM [J].
BLUMENFELD, JD ;
SEALEY, JE ;
SCHLUSSEL, Y ;
VAUGHAN, ED ;
SOS, TA ;
ATLAS, SA ;
MULLER, FB ;
ACEVEDO, R ;
ULICK, S ;
LARAGH, JH .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (11) :877-885
[6]  
Born-Frontsberg E, 2009, J CLIN ENDOCRINOLOGY
[7]   Adrenocortical tumors: Recent advances in basic concepts and clinical management [J].
Bornstein, SR ;
Stratakis, CA ;
Chrousos, GP .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (09) :759-771
[8]   COMPARISON OF SURGERY AND PROLONGED SPIRONOLACTONE THERAPY IN PATIENTS WITH HYPERTENSION, ALDOSTERONE EXCESS, AND LOW PLASMA-RENIN [J].
BROWN, JJ ;
ROBERTSON, JI ;
HAYWOOD, E ;
LEVER, AF ;
FERRISS, JB ;
FRASER, R ;
DAVIES, DL .
BMJ-BRITISH MEDICAL JOURNAL, 1972, 2 (5816) :729-+
[9]   Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension [J].
Burgess, ED ;
Lacoucière, Y ;
Ruilope-Urioste, LM ;
Oparil, S ;
Kleiman, JH ;
Krause, S ;
Roniker, B ;
Maurath, C .
CLINICAL THERAPEUTICS, 2003, 25 (09) :2388-2404
[10]   THE ABSENCE OF LONG-TERM THERAPEUTIC EFFECT OF CALCIUM-CHANNEL BLOCKADE IN THE PRIMARY ALDOSTERONISM OF ADRENAL ADENOMAS [J].
BURSZTYN, M ;
GROSSMAN, E ;
ROSENTHAL, T .
AMERICAN JOURNAL OF HYPERTENSION, 1988, 1 (03) :S88-S90